CT HB05610

Adds definitions for epilepsy, seizures, and antiepileptic drugs to section 20-619, with epilepsy defined as a neurological condition characterized by recurrent seizures.

Prohibits pharmacists from substituting antiepileptic drugs or changing drug manufacturers without prior written consent from the patient's prescribing practitioner, even if the substitute is therapeutically equivalent.

Requires pharmacists to notify prescribing practitioners of any proposed antiepileptic drug substitution or manufacturer change via electronic mail or facsimile and obtain written consent before proceeding.

Allows pharmacists to exercise professional judgment in refilling antiepileptic prescriptions if unable to contact the prescribing practitioner after reasonable efforts, or to return the prescription to the patient for filling elsewhere if consent is not obtained.

Effective October 1, 2011, with amendments to sections 20-619 and 17b-493 of the general statutes.